Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents (COVIDIV)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Completed

Conditions: Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion

Treatments: Procedure: Questionnaire; Other: Data collection up to 1 year

Study type: Observational

Funder types: NETWORK

Identifiers

NCT04395859

MMT_2020_15

Details and patient eligibility

About

In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months.

The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

Enrollment: 233 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ocular pathology requiring repeated IVT treatment of anti-angiogenic drugs (exudative AMD, diabetic macular edema or secondary to retinal venous occlusion ...)
• Beginning of IVT treatment repeated before 10/01/2019 (6 months before the start of French confinement)

Exclusion criteria

• Refusal to participate

Trial design

233 participants in 1 patient group

Patients treated with IVT before COVID19 pandemia

Description:

Treatment started at least 6 months before the French confinement for COVID19 (15th march 2020)

Treatment:

Procedure: Questionnaire

Other: Data collection up to 1 year